SCHEMBL6484697

SCHEMBL6484697

O=S(=O)(Nc1ccc2c(OCc3nc(-c4ccc(F)cc4)no3)cccc2c1)C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 1/20 0.49
MAPT P10636 8/20 0.42
GSTP1 P09211 2/20 0.42
MAPK1 P28482 3/20 0.41
TSHR P16473 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
HDAC4 P56524 2/20 0.41
HDAC6 Q9UBN7 1/20 0.41
CYSLTR2 Q9NS75 1/20 0.41
CYSLTR1 Q9Y271 1/20 0.41
FFAR1 O14842 1/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 4/20 0.40
TP53 P04637 3/20 0.40
HPGD P15428 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6477186 0.93 PPARA (0.47) PPARAMAPTMAPK1TSHRTDP1
SCHEMBL6477166 0.93 MAPK1 (0.52) PPARAMAPTMAPK1TSHRTDP1
SCHEMBL6486872 0.91 PPARA (0.46) PPARAMAPTMAPK1TSHRTDP1
SCHEMBL6476402 0.91 PPARA (0.50) PPARAMAPTGSTP1MAPK1TSHR
SCHEMBL6486994 0.89 FFAR1 (0.49) PPARAMAPTL3MBTL1CYSLTR2CYSLTR1
SCHEMBL6486939 0.85 CNR2 (0.40) PPARATSHRHDAC6CYSLTR2CYSLTR1
SCHEMBL6487120 0.83 CYSLTR2 (0.44) CYSLTR2CYSLTR1NPC1RAB9AMEN1
SCHEMBL6485332 0.81 CYSLTR2 (0.41) CYSLTR2CYSLTR1
SCHEMBL6476719 0.80 CYSLTR2 (0.49) CYSLTR2CYSLTR1
SCHEMBL6488956 0.80 AGXT (0.42) CYSLTR2CYSLTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6933322-B2 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2005-08-23 US disclosed
US-20030216442-A1 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus WYETH 2003-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216442-A1 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus INSR, GPR119, SLC5A1 PPARA 491/4885MAPT 4257/4885GSTP1 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.